Small Molecule Programs
Oyster Point has pioneered the administration of selective cholinergic agonist nasal sprays to activate the parasympathetic pathway and stimulate natural tear production, as shown in preclinical and clinical studies. We are focused on the development of OC-01 (varenicline solution) nasal spray for the treatment of the signs and symptoms of dry eye disease, as well as leading and supporting development for a number of potential indications and uses associated with, and beyond, dry eye disease. These include neurotrophic keratopathy, dry eye associated with contact lens intolerance, and ocular surface preparation for refractive surgeries. We believe that targeting the parasympathetic nervous system through the use of locally administered selective cholinergic agonists, such as OC-01 (varenicline solution) nasal spray, has the potential to treat a wide range of diseases and disorders.
OC-01 (varenicline solution) nasal spray is an investigational drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline solution) nasal spray have not been established.
Enriched Tear Film (ETF™) Gene Therapy
Adeno-associated virus (AAV) vectors are nonreplicating DNA delivery vehicles that are currently not known to cause disease.
OC-101 (AAV-NGF) is Oyster Point’s investigational gene therapy in development as part of Oyster Point’s proprietary development approach of leveraging ETF™ Gene Therapy to treat select ocular surface diseases. OC-101 is an AAV containing the nerve growth factor (NGF) gene. NGF is a naturally occurring protein secreted by cells on the surface of the cornea and involved in the diﬀerentiation and maintenance of neurons that has been shown to heal the corneal epithelium and improve corneal sensitivity.1 Once administered to the lacrimal gland, OC-101 (AAV-NGF) has been shown in preclinical studies to harness the body’s protein-producing machinery to produce NGF, which was then secreted into the tear ﬁlm and onto the ocular surface.
OC-101 (AAV-NGF) is an investigational gene therapy that has not been tested in humans and has not been approved for any use in any country. The safety and efficacy of OC-101 (AAV-NGF) have not been established.
Bacteriophage (“Phage”) Research Collaboration
Oyster Point has partnered in a research collaboration to develop unique therapies to potentially treat bacterial infections in ophthalmology using bacteriophages. Bacteriophages, also known as “phages,” are viruses that are found in the natural environment that infect and replicate, specifically in bacteria. Interestingly, bacteriophages collectively constitute a majority of organisms found on planet Earth. Bacteriophages are generally safe to humans and are targeted in their ability to infect specific strains of bacteria. Once a bacteriophage attaches to a susceptible bacterium, it causes the host cell to die, releasing new bacteriophage to infect other bacteria, thus increasing the dose at the site of the disease.
Collaborate to Innovate
Oyster Point is driven to research, develop, and commercialize innovative ophthalmic therapies that have the potential to change patients’ lives. We value collaboration with partners who share our mission and have the expertise, curiosity, and ingenuity to reimagine ophthalmic research and development and accelerate the pathway toward delivering for patients.
We have embraced different forms of collaboration, including traditional licensing agreements and research collaborations, and welcome additional opportunities for research, development, and global commercialization that may complement our internal capabilities with the technology, know-how, and experience of exceptional partners.
Interested in collaborating with our team?
1. Mastropasqua L, Lanzini M, Dua HS, et al (2020). In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. Am J Opthalmol. 217, 278-286.